Literature DB >> 8207045

Influence of cytokines on mdr1 expression in human colon carcinoma cell lines: increased cytotoxicity of MDR relevant drugs.

W Walther1, U Stein.   

Abstract

We investigated the effects of tumor necrosis factor (TNF) alpha, interferon (IFN) gamma and interleukin-2 (IL-2) on the mdr1 gene expression in four human colon carcinoma cell lines (Lo Vo, HT 115, SW 480, and LS 174T) at different times (8, 24, 48, and 72 h). We found no significant changes in mdr1 expression after 8 h and 24 h of cytokine treatment in all four lines. After 48 h and 72 h, however, a marked reduction of mdr1 expression in Lo Vo, HT 115, and SW 480 cells and an unaffected expression in LS 174T cells was observed. We examined whether the cytokine-mediated reduction of mdr1 expression correlates to the multidrug resistance (MDR) phenotype. In those cell lines showing a decreased mdr1 expression after a long-term cytokine pretreatment we found a dramatic enhancement of cytotoxicity of the MDR relevant drugs vincristine and doxorubicin, whereas LS 174T cells remained resistant. By contrast, the simultaneous application of cytokines and cytostatics caused no additive or synergistic effects. We conclude that in certain colon carcinoma cell lines a decreased mdr1 expression caused by prolonged cytokine pretreatment correlates with an enhanced cytotoxicity of drugs susceptible to MDR as an MDR-overcoming effect.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8207045     DOI: 10.1007/bf01191800

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  33 in total

1.  P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines.

Authors:  G M Lai; Y N Chen; L A Mickley; A T Fojo; S E Bates
Journal:  Int J Cancer       Date:  1991-11-11       Impact factor: 7.396

2.  Classification of human colorectal adenocarcinoma cell lines.

Authors:  A Leibovitz; J C Stinson; W B McCombs; C E McCoy; K C Mazur; N D Mabry
Journal:  Cancer Res       Date:  1976-12       Impact factor: 12.701

Review 3.  Genetic aspects of multidrug resistance.

Authors:  J L Biedler
Journal:  Cancer       Date:  1992-09-15       Impact factor: 6.860

Review 4.  Tumor necrosis factor activities and cancer therapy--a perspective.

Authors:  R S Sidhu; A P Bollon
Journal:  Pharmacol Ther       Date:  1993-01       Impact factor: 12.310

5.  Staurosporine reduces P-glycoprotein expression and modulates multidrug resistance.

Authors:  K E Sampson; C L Wolf; I Abraham
Journal:  Cancer Lett       Date:  1993-01-15       Impact factor: 8.679

6.  Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists.

Authors:  C E Herzog; M Tsokos; S E Bates; A T Fojo
Journal:  J Biol Chem       Date:  1993-02-05       Impact factor: 5.157

7.  Modulation of activity of the promoter of the human MDR1 gene by Ras and p53.

Authors:  K V Chin; K Ueda; I Pastan; M M Gottesman
Journal:  Science       Date:  1992-01-24       Impact factor: 47.728

Review 8.  The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo.

Authors:  I B Roninson
Journal:  Biochem Pharmacol       Date:  1992-01-09       Impact factor: 5.858

9.  Chemosensitivity patterns and expression of human multidrug resistance-associated MDR1 gene by human gastric and colorectal carcinoma cell lines.

Authors:  J G Park; B S Kramer; S L Lai; L J Goldstein; A F Gazdar
Journal:  J Natl Cancer Inst       Date:  1990-02-07       Impact factor: 13.506

Review 10.  Multidrug resistance (mdr) genes in human cancer.

Authors:  K Nooter; H Herweijer
Journal:  Br J Cancer       Date:  1991-05       Impact factor: 7.640

View more
  9 in total

Review 1.  Immunotherapy: a useful strategy to help combat multidrug resistance.

Authors:  Tyler J Curiel
Journal:  Drug Resist Updat       Date:  2012-04-05       Impact factor: 18.500

2.  Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial.

Authors:  Lynn G Feun; Christopher O'Brien; Enrique Molina; Miguel Rodriguez; Lenox Jeffers; Eugene R Schiff; Angela Marini; Niramol Savaraj; Bach Ardalan
Journal:  J Cancer Res Clin Oncol       Date:  2003-01-09       Impact factor: 4.553

3.  Synergistic effect of bromocriptine and tumor necrosis factor-alpha on reversing hepatocellular carcinoma multidrug resistance in nude mouse MDR1 model of liver neoplasm.

Authors:  Lei Ding; Xiao-Ping Chen; Zhi-Wei Zhang; Jian Guan; Wan-Guang Zhang; Hai-Ping Wang; Zhi-Hui Wang; Chun-Lei Li
Journal:  World J Gastroenterol       Date:  2005-09-28       Impact factor: 5.742

4.  Decreased expression and activity of P-glycoprotein in rat liver during acute inflammation.

Authors:  M Piquette-Miller; A Pak; H Kim; R Anari; A Shahzamani
Journal:  Pharm Res       Date:  1998-05       Impact factor: 4.200

5.  Interleukin-1 beta and tumor necrosis factor-alpha increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX.

Authors:  Fatemeh Mosaffa; Hermann Lage; Jalil Tavakol Afshari; Javad Behravan
Journal:  Inflamm Res       Date:  2009-03-31       Impact factor: 4.575

6.  Cytokine-mediated reversal of multidrug resistance.

Authors:  U Stein; W Walther
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

7.  Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance.

Authors:  U Stein; W Walther; R H Shoemaker
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

Review 8.  Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches.

Authors:  Talha Bin Emran; Asif Shahriar; Aar Rafi Mahmud; Tanjilur Rahman; Mehedy Hasan Abir; Mohd Faijanur-Rob Siddiquee; Hossain Ahmed; Nova Rahman; Firzan Nainu; Elly Wahyudin; Saikat Mitra; Kuldeep Dhama; Mahmoud M Habiballah; Shafiul Haque; Ariful Islam; Mohammad Mahmudul Hassan
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738

9.  The Changes of P-glycoprotein Activity by Interferon-γ and Tumor Necrosis Factor-α in Primary and Immortalized Human Brain Microvascular Endothelial Cells.

Authors:  Na-Young Lee; Peter Rieckmann; Young-Sook Kang
Journal:  Biomol Ther (Seoul)       Date:  2012-05       Impact factor: 4.634

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.